Q-omics provides the consensus-scored NR4A1AS profile across patient tissues and cancer cell-line models. NR4A1AS expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NR4A1AS is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, NR4A1AS RNA expression shows 11,366 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and BLCA as cancer lineages where NR4A1AS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NR4A1AS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NR4A1AS survival associations across molecular data types. NR4A1AS RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NR4A1AS RNA expression–survival associations across cancer types. High NR4A1AS expression shows unfavorable associations in UVM, COAD and LUSC, but favorable associations in KICH, BRCA and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NR4A1AS RNA expression.
This table summarizes NR4A1AS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for NR4A1AS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NR4A1AS shows lower tumor expression in BLCA, THCA, KIRP, KICH, HNSC and UCEC. The BLCA box plot shows higher NR4A1AS RNA expression in normal versus tumor tissue (log2 FC = −2.680, t-test p < 0.001).
This table shows molecular features associated with NR4A1AS in patient tissues and cancer cell lines. In patient samples, NR4A1AS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
